An Exploratory Pharmacokinetic, Pharmacodynamic and Safety Study of XP21279 (With Lodosyn) and Sinemet in Parkinson's Disease Subjects With Motor Fluctuations.
Phase of Trial: Phase I/II
Latest Information Update: 18 May 2011
At a glance
- Drugs XP 21279 (Primary) ; Carbidopa; Levodopa/carbidopa
- Indications Parkinson's disease
- Focus Pharmacokinetics
- Sponsors XenoPort
- 12 Mar 2010 Actual end date (Jan 2010) added as reported by ClinicalTrials.gov.
- 12 Mar 2010 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 23 Feb 2010 Phase I results in 10 patients reported by Xenoport.